Publications
Detailed Information
Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: Susceptibility and clinical outcome
Cited 17 time in
Web of Science
Cited 15 time in Scopus
- Authors
- Issue Date
- 2013-04
- Publisher
- Taylor & Francis
- Citation
- Scandinavian Journal of Infectious Diseases, Vol.45 No.4, pp.315-319
- Abstract
- Although tigecycline is considered one of the few therapeutic options for carbapenem-resistant Acinetobacter baumannii (CRAB) bacteraemia, its role in the treatment of CRAB bacteraemia remains unclear. We describe the clinical outcomes of 9 patients who received tigecycline for CRAB bacteraemia. Although all CRAB blood isolates were susceptible to tigecycline, 5 (56%) deaths were related to CRAB bacteraemia and 1 case of breakthrough CRAB bacteraemia was observed during tigecycline therapy. Clinical outcomes of tigecycline therapy may be poor in patients with tigecycline-susceptible CRAB bacteraemia, although multiple factors including delayed treatment could contribute to the poor outcomes.
- ISSN
- 0036-5548
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.